Back HCV Disease Progression Transplant/Artificial Liver

Liver Transplant - HCV

Increased Distance Reduces Likelihood of Liver Transplant

alt

Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.

Read more:

AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis

Hepatitis C patients who took low-dose aspirin after liver transplantation experienced slower fibrosis progression, researchers reported at the AASLD Liver Meeting this month in Washington, DC. Two other studies showed that cenicriviroc -- a drug being developed for HIV treatment that blocks both CCR5 and CCR2 cell surface receptors -- had anti-inflammatory and anti-fibrotic activity in mice and rats.

alt

Read more:

AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%

Simeprevir added to pegylated interferon and ribavirin performed well in difficult-to-treat treatment-naive patients and prior relapsers with genotype 1 chronic hepatitis C, according to 2 poster presentations at the 64th AASLD Liver Meeting last week in Washington, DC, as described in an announcement by Janssen.

alt

Read more:

AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated

Hepatitis C treatment that leads to viral suppression significantly reduces the likelihood of liver disease progression and liver-related mortality, but most patients remain untreated, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC. Other studies found that a growing proportion of liver transplants are due to hepatocellular carcinoma, which can still occur even after treatment.

alt

Read more:

AASLD 2013: Sofosbuvir Taken Before or After Liver Transplant Reduces HCV Recurrence

An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly two-thirds of patients, while the same regimen led to early viral clearance in three-quarters of those treated after transplantation, according to studies presented this week at the 64thAASLD Liver Meeting in Washington, DC.

alt

Read more: